Chemical structure of molecule Ulotaront (SEP-363856)

TAAR1 GPCR agonist

phase III candidate for schizophrenia

from in vivo phenotypic screening

ACS Medicinal Chemistry Letters

Sunovion Pharmaceuticals, Marlborough, MA

Ulotaront (SEP-363856) is a Phase III candidate with FDA Breakthrough Therapy Designation for the treatment of schizophrenia with demonstrated efficacy based on a physician-rated scale (PANSS) in a 4-week…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.